These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

170 related articles for article (PubMed ID: 24336430)

  • 21. Heart failure and the risk of shocks in patients with implantable cardioverter defibrillators: results from the Triggers Of Ventricular Arrhythmias (TOVA) study.
    Whang W; Mittleman MA; Rich DQ; Wang PJ; Ruskin JN; Tofler GH; Muller JE; Albert CM;
    Circulation; 2004 Mar; 109(11):1386-91. PubMed ID: 14993132
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Are MADIT II criteria for implantable cardioverter defibrillator implantation appropriate for Chinese patients?
    Siu CW; Pong V; Ho HH; Liu S; Lau CP; Li SW; Tse HF
    J Cardiovasc Electrophysiol; 2010 Mar; 21(3):231-5. PubMed ID: 19804551
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Posttraumatic stress symptoms and predicted mortality in patients with implantable cardioverter-defibrillators: results from the prospective living with an implanted cardioverter-defibrillator study.
    Ladwig KH; Baumert J; Marten-Mittag B; Kolb C; Zrenner B; Schmitt C
    Arch Gen Psychiatry; 2008 Nov; 65(11):1324-30. PubMed ID: 18981344
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Mortality and appropriate and inappropriate therapy in patients with ischaemic heart disease and implanted cardioverter-defibrillators for primary prevention: data from the Danish ICD Register.
    Weeke P; Johansen JB; Jørgensen OD; Nielsen JC; Møller M; Videbæk R; Højgaard MV; Riahi S; Jacobsen PK
    Europace; 2013 Aug; 15(8):1150-7. PubMed ID: 23407630
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Long-term benefit of primary prevention with an implantable cardioverter-defibrillator: an extended 8-year follow-up study of the Multicenter Automatic Defibrillator Implantation Trial II.
    Goldenberg I; Gillespie J; Moss AJ; Hall WJ; Klein H; McNitt S; Brown MW; Cygankiewicz I; Zareba W;
    Circulation; 2010 Sep; 122(13):1265-71. PubMed ID: 20837894
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Comorbidity burden is associated with poor psychological well-being and physical health status in patients with an implantable cardioverter-defibrillator.
    Hoogwegt MT; Kupper N; Jordaens L; Pedersen SS; Theuns DA
    Europace; 2013 Oct; 15(10):1468-74. PubMed ID: 23608028
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Right ventricular pacing is associated with impaired overall survival, but not with an increased incidence of ventricular tachyarrhythmias in routine cardioverter/defibrillator recipients with reservedly programmed pacing.
    Stockburger M; Celebi O; Krebs A; Knaus T; Nitardy A; Habedank D; Dietz R
    Europace; 2009 Jul; 11(7):924-30. PubMed ID: 19447808
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Long-term follow-up of implantable cardioverter-defibrillator for secondary prevention in chagas' heart disease.
    Martinelli M; de Siqueira SF; Sternick EB; Rassi A; Costa R; Ramires JA; Kalil Filho R
    Am J Cardiol; 2012 Oct; 110(7):1040-5. PubMed ID: 22727179
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Long-term comparison of the implantable cardioverter defibrillator versus amiodarone: eleven-year follow-up of a subset of patients in the Canadian Implantable Defibrillator Study (CIDS).
    Bokhari F; Newman D; Greene M; Korley V; Mangat I; Dorian P
    Circulation; 2004 Jul; 110(2):112-6. PubMed ID: 15238454
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Age dependent efficacy of implantable cardioverter-defibrillator treatment: observations in 450 patients over an 11 year period.
    Trappe HJ; Pfitzner P; Achtelik M; Fieguth HG
    Heart; 1997 Oct; 78(4):364-70. PubMed ID: 9404252
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Impact of age and medical comorbidity on the effectiveness of implantable cardioverter-defibrillators for primary prevention.
    Chan PS; Nallamothu BK; Spertus JA; Masoudi FA; Bartone C; Kereiakes DJ; Chow T
    Circ Cardiovasc Qual Outcomes; 2009 Jan; 2(1):16-24. PubMed ID: 20031808
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The effect of spironolactone on ventricular tachyarrhythmias in patients with implantable cardioverter-defibrillators.
    Zarraga IG; Dougherty CM; MacMurdy KS; Raitt MH
    Circ Arrhythm Electrophysiol; 2012 Aug; 5(4):739-47. PubMed ID: 22773022
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Patient-Reported Quality of Life as a Predictor of Mortality and Ventricular Tachyarrhythmia's During 7 Years' Follow-Up in Patients With an Implantable Cardioverter Defibrillator (from the MIDAS Study).
    van Veen B; Andersen CM; Johansen JB; Theuns DA; Pedersen SS
    Am J Cardiol; 2019 Feb; 123(4):605-610. PubMed ID: 30553508
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Clinical predictors of appropriate implantable-cardioverter defibrillator discharge.
    Catanzaro JN; Makaryus AN; Sison C; Vavasis C; Donaldson D; Beldner S; Boal B; Jadonath R
    Pacing Clin Electrophysiol; 2007 Jan; 30 Suppl 1():S120-4. PubMed ID: 17302686
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The gender-paradox among patients with implantable cardioverter-defibrillators: a propensity-matched study.
    Bhavnani SP; Pavuluri V; Coleman CI; Guertin D; Yarlagadda RK; Clyne CA; Kluger J
    Pacing Clin Electrophysiol; 2013 Jul; 36(7):878-84. PubMed ID: 23614760
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Greater mortality risk among patients with delayed follow-up after implantable cardioverter defibrillator procedures.
    Laksman ZW; Krahn AD; Dorian P; Simpson CS; Crystal E; Healey JS; Khaykin Y; Wang X; Lee DS
    Can J Cardiol; 2014 Jun; 30(6):598-605. PubMed ID: 24882529
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Incidence and predictors of implantable cardioverter-defibrillator therapy in patients with arrhythmogenic right ventricular dysplasia/cardiomyopathy undergoing implantable cardioverter-defibrillator implantation for primary prevention.
    Bhonsale A; James CA; Tichnell C; Murray B; Gagarin D; Philips B; Dalal D; Tedford R; Russell SD; Abraham T; Tandri H; Judge DP; Calkins H
    J Am Coll Cardiol; 2011 Sep; 58(14):1485-96. PubMed ID: 21939834
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Sleep-disordered breathing in patients with implantable cardioverter-defibrillator.
    Grimm W; Apelt S; Timmesfeld N; Koehler U
    Europace; 2013 Apr; 15(4):515-22. PubMed ID: 23129543
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Psychological indices as predictors for phantom shocks in implantable cardioverter defibrillator recipients.
    Starrenburg A; Kraaier K; Pedersen S; Scholten M; Van Der Palen J
    Pacing Clin Electrophysiol; 2014 Jun; 37(6):768-73. PubMed ID: 24456312
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Anxiety, depression, ventricular arrhythmias and mortality in patients with an implantable cardioverter defibrillator: 7 years' follow-up of the MIDAS cohort.
    Andersen CM; Theuns DAMJ; Johansen JB; Pedersen SS
    Gen Hosp Psychiatry; 2020; 66():154-160. PubMed ID: 32866884
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.